High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients

Acta Haematologica

Volumn 124, Issue 4, 2010, Pages 214-217

  Gary, Thomas ^a   Hafner, Franz ^a   Froehlich, Harald ^a   Stojakovic, Tatjana ^a   Scharnagl, Hubert ^a   Pilger, Ernst ^a   Brodmann, Marianne ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGED; AGING; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; KOLMOGOROV SMIRNOV TEST; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; FACTOR V; FACTOR VIII; FACTOR XII; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; VENOUS THROMBOEMBOLISM;

EID: 78149294768     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321530     Document Type: Article

References (23)

1. Jacobs LG: Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients. J Am Geriatr Soc 2003; 51: 1472-1478.
2. Sellier E, Labarere J, Sevestre MA, Belmin J, Thiel H, Couturier P, Bosson JL: Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France. J Am Geriatr Soc 2008; 56: 224-230.
3. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. 1. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479.
4. Abbate R, Prisco D, Rostagno C, Boddi M, Gensini GF: Age-related changes in the hemostatic system. Int J Clin Lab Res 1993; 23: 1-3.
5. Hager K, Setzer J, Vogl T, Voit J, Platt D: Blood coagulation factors in the elderly. Arch Gerontol Geriatr 1989; 9: 277-282.
6. Ofosu FA, Craven S, Dewar L, Anvari N, Andrew M, Blajchman MA: Age-related changes in factor VII proteolysis in vivo. Br J Haematol 1996; 94: 407-412.
7. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H: Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. 1. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-784.
8. Sagripanti A, Carpi A: Natural anticoagulants, aging, and thromboembolism. Exp Gerontol 1998; 33: 891-896.
9. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA: Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005; 93: 842-846.
10. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-462. (Pubitemid 30646484)
11. Kraaijenhagen RA, Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Büller HR: High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
12. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P: The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-1783.
13. Bank I, van de Poel MH, Coppens M, Hamulyák K, Prins MH, van der Meer J, Veeger NJ, Büller HR, Middeldorp S: Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. A prospective family cohort study. Thromb Haemost 2007; 98: 1040-1044.
14. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR: High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
15. Bach J, Endler G, Winkelmann BR, Hamulyák K, Prins MH, van der Meer J, Veeger NJ, Büller HR, Middeldorp S: Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-296.
16. Doggen CJ, Rosendaal FR, Meijers JC: Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-4051.
17. Braat EA, Dooijewaard G, Rijken DC: Fibrinolytic properties of activated FXII. Eur J Biochem 1999; 263: 904-911.
18. Bradford HN, Pixley RA, Colman RW: Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 22756-22763.
19. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-2247.
20. Jones DW, Gallimore MJ, Winter M: Pseudo factor XII deficiency and phospholipid antibodies. Thromb Haemost 1996; 75: 696-697.
21. Koster T, Rosendaal FR, Briet E, Vandenbroucke JP: John Hageman's factor and deepvein thrombosis: Leiden thrombophilia study. Br J Haematol 1994; 87: 422-424.
22. Schulman S, Wiman B: The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost 1996; 75: 607-611.
23. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH: Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-1827.